A Study Evaluating Nexagon™ in the Treatment of Skin Wounds.

Inclusion criteria

• Healthy male or female subjects.
• Fair skinned (Fitzpatrick Classification Level I - III).
• Aged between 18 and 40 years inclusive.
• Subjects who are able to comply with all study procedures, including follow-up assessment visits.
• Subjects who are willing and able to give written informed consent to take part in the study.

Exclusion criteria

• Subjects who have pigmented skin due to an increased susceptibility to hypertrophic and keloid scarring (Fitzpatrick Classification Level IV - VI).
• Subjects who are known hypertrophic or keloid scar formers.
• Subjects who smoke.
• Subjects with a body mass index of greater than 30 kg/m2.
• Subjects with bleeding disorders or taking anti-coagulants.
• Subjects with any other skin lesion sites or a chronic or currently active skin disorder, which would adversely affect the healing of the acute wounds or which involve the areas to be examined in this study.
• Subjects taking or who have taken prescribed drugs in the 30 days prior to Day 0, in particular, topical or systemic steroids, anti-inflammatories, anti-coagulants, anti-proliferative drugs, or antibiotics.
• Subjects who regularly take aspirin, ginseng, gilboa, Alka Seltzer or any other over-the-counter medicine or complimentary health product that can affect the blood clotting process.
• Subjects with a history of clinically relevant allergies.
• Subjects with tattoos, scars or abrasions at the site to be studied.
• Subjects with any clinically significant abnormality following review of pre-study laboratory data and physical examination.
• Subjects showing evidence of drug abuse.
• Subjects with any clinically significant mental illness in the opinion of the Investigator.
• Females who are currently pregnant or breast-feeding. Females of child-bearing potential must commit to consistent and correct use of an acceptable method of birth control, as defined the protocol.
• Subjects who have a past or present disease, which as judged by the Investigator may affect the safety of the subject or the outcome of the study.
• Subjects who have participated in a clinical study within the 30 days prior to Day 0.